MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer

2019112 citationsJournal Articlegold Open Access

Authors

Jingyan Yi · Dalian Medical University

Chongya Liu · Dalian Medical University

Zhiwei Tao · Dalian Medical University

Min Wang · Dalian Medical University

Yaxun Jia · Dalian Medical University

Xiaolin Sang · Dalian Medical University

Lanlin Shen ·

Abstract

Our data provide a rationale for clinical evaluation of therapeutic synergy of these two classes of inhibitors in ovarian cancer patients whose tumors show high MYC expression and who do not respond to PARP inhibitors or CDK4/6 inhibitors monotherapies. FUND: This work was supported by the National Natural Science Foundation of China [81672575, 81874111, 81472447 to HC; 81572586 and 81372853 to PL], and the Liaoning Provincial Key Basic Research Program for Universities [LZ2017002 to HC].

Topics & Keywords

PARP inhibition in cancer therapy Advanced Breast Cancer Therapies Calcium signaling and nucleotide metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: EBioMedicine

Volume 43, pp. 225-237

DOI: 10.1016/j.ebiom.2019.03.027

Field-Weighted Citation Impact: 6.77